Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/65769
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine |
Author: | Baune, B. |
Citation: | Neuropsychiatric Disease and Treatment, 2008; 4(6):1181-1192 |
Publisher: | Dove Medical Press Ltd. |
Issue Date: | 2008 |
ISSN: | 1176-6328 1178-2021 |
Statement of Responsibility: | Bernhard T. Baune |
Abstract: | Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD. |
Keywords: | quetiapine major depressive disorders general anxiety disorder randomized controlled studies adverse effects |
Rights: | © 2008 Dove Medical Press Limited. All rights reserved. |
DOI: | 10.2147/NDT.S3238 |
Published version: | http://dx.doi.org/10.2147/ndt.s3238 |
Appears in Collections: | Aurora harvest Psychiatry publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.